Biomarker Exposure-Response Analysis in Mild-To-Moderate Alzheimer's Disease Trials of Bapineuzumab.

Russu A, Samtani MN, Xu S, Adedokun OJ, Lu M, Ito K, Corrigan B, Raje S, Liu E, H Brashear R, et al.

J Alzheimers Dis. 2016 May 03; 53(2):535-46. PMID: 27163805. Abstract